Skip to content

Young survivor cohort with menopause after gynecologic cancer treatment

Young survivor cohort with menopause after gynecologic cancer treatment

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0009567
Enrollment
400
Registered
2024-06-25
Start date
2023-08-29
Completion date
Unknown
Last updated
2024-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Yonsei University Health System, Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Primary female cancer (ovarian cancer, endometrial cancer, cervical cancer, uterine body cancer, uterine sarcoma, ovarian cancer, vaginal cancer, vulva cancer, peritoneal cancer), or ovarian borderline tumor or 0 strange rock formations (pre-cancer) has been diagnosed 2. I was diagnosed with menopause at the age of 43 years old 3. Menopause is defined as follows; 1) or 2) satisfied 1)More than a year after chemotherapy was completed, Serum FSH=25mIU/mL or serum AMH <0.2ng/mL, performed at intervals of more than one month 2)A person who has undergone bilateral ovarian resection or bilateral ovarian tube resection 4. The age at the time of cohort registration is under 45 years old

Exclusion criteria

Exclusion criteria: 1. have metastatic cancer in female reproductive organs 2. Those who cannot fully understand the explanation related to this study because Korean is not their first language

Design outcomes

Primary

MeasureTime frame
Identifying Osteoporosis Incidence in Young Female Cancer Survivors Diagnosed with Early Ovarian Failure

Secondary

MeasureTime frame
Check the incidence of metabolic syndrome in young female cancer survivors diagnosed with early ovarian failure;The extent of bone density and muscle mass reduction in young female cancer survivors diagnosed with early ovarian failure;Suggestions on the timing and application of standardized hormone supplementation therapy according to carcinoma in young female cancer survivors diagnosed with early ovarian failure

Countries

Korea, Republic of

Contacts

Public Contactyun jung choi

Koera University Guro Hospital

yungjung2023@gmail.com+82-70-8835-3515

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026